| Closed Market –
22:00:00 27/06/2024 | Varies. 5j. | Varia. Jan 1 | ||
| 12,83 | -2,14 % | -8,75 % | +167,29 % | |
A panel of experts outside the US Centers for Disease Control and Prevention (CDC) has recommended the use of updated COVID-19 vaccines, as authorized by the FDA, in people aged six months and older for the 2024-25 vaccination campaign. (Reporting by Christy Santhosh and Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Go to the original article.
Legal Disclaimer
Legal warning
Contact us for any correction request
© Reuters – 2024
| U.S. CDC Advisors Recommend Updated COVID Vaccines for People Aged Six Months and Older | 27/06 | RE |
| Novavax: requests the EMA for its Covid vaccine from 12 years old | 24/06 | CF |
| Novavax seeks EU approval for updated Covid-19 vaccine | 24/06 | MT |
| Novavax files emergency use authorization for updated COVID-19 vaccine | 14/06 | MT |
| FDA asks COVID vaccine makers to target KP.2 strain with updated vaccines | 14/06 | RE |
| Novavax, Inc. Files Application with FDA for its Updated Protein-Based COVID-19 Vaccine for 2024-2025 Formula | 14/06 | CI |
| COVID vaccines should target JN.1 variants in 2024-25 campaign, US FDA says | 07/06 | RE |
| S&P 500, Nasdaq fall ahead of US jobs data | 06/06 | RE |
| Wall Street in mixed tones, Nvidia’s decline hurting tech stocks; jobs figures in sight | 06/06 | RE |
| Novavax Announces FDA Has Set Target Date for Review of Biologics License Application for Covid-19 Vaccine | 06/06 | MT |
| COVID vaccines against JN.1 variant neutralize new strains, vaccine makers say | 05/06 | RE |
| COVID vaccines expected to target JN.1 and KP.2 subvariants in 2024-25 campaign, US FDA staff say | 03/06 | RE |
| Sanofi and Novavax announce a co-exclusive licensing agreement for the commercialization of the Covid-19 vaccine and the development of new combined influenza-Covid-19 vaccines | 28/05 | CI |
| Novavax awaits FDA decision on whether its next COVID vaccine can be offered in the United States | 24/05 | RE |
| NOVAVAX, INC. : B. Riley favorable on the file | 24/05 | ZM |
| Novavax, Inc. Announces Retirement of Filip Dubovsky as President, Research and Development, Effective June 30, 2024 | 23/05 | CI |
| Novavax: 1st shipment of the R21/MatrixM malaria vaccine | 21/05 | CF |
| Shah Capital ends campaign against Novavax board after Sanofi deal | 20/05 | RE |
| Novavax Shareholder Shah Capital Withdraws Campaign Against Director Re-Election | 20/05 | MT |
| Shah Capital Withdraws Campaign Against Novavax Directors After Sanofi Settlement | 20/05 | RE |
| Shah Capital Withdraws Campaign Against Three Novavax Directors | 20/05 | RE |
| Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM | 16/05 | |
| The most talked-about stocks on Reddit subforum Wallstreetbets were mostly up before the bell Tuesday; AMC Entertainment, GameStop lead the way | 14/05 | MT |
| Meme stocks roar again | 14/05 | |
| Live from the Markets: Veolia, Stellantis, BNP Paribas, Bayer, Anglo American, Rheinmetall, Uber… | 14/05 |
Duration Auto. 2 months 3 months 6 months 9 months 1 an 2 ans 5 ans 10 ans Max.
Period Jour Week
More graphics
Novavax, Inc. is a biotechnology company that discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company offers a differentiated vaccine platform that combines a recombinant protein-based approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance immune response. It has a commercial program, for COVID-19 vaccines, which includes the Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and the updated Nuvaxovid COVID-19 vaccine (NVX-CoV2601 or vaccine updated) (collectively, the COVID-19 vaccine). The Company is continuing the development of other vaccine candidates, including its COVID19-combined influenza (CIC) vaccine candidate and other vaccine candidates. The COVID-19 vaccine and its other vaccine candidates incorporate the company’s proprietary Matrix-M adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.
More information about the company
Purchase
Average recommendation
ACCUMULATE
Last Closing Price
12,83
USD
Average course objective
22,8
USD
Deviation / Average Target
+77,71 %
Consensus
| Varia. Jan 1 | Capi. | |
|---|---|---|
| +167,29 % | 1,8 Md | |
| +21,85 % | 46,44 Md | |
| +38,65 % | 39,1 Md | |
| -8,05 % | 38,76 Md | |
| +29,04 % | 31,24 Md | |
| -13,75 % | 25,8 Md | |
| +10,65 % | 25,9 Md | |
| +38,43 % | 13,12 Md | |
| -6,92 % | 11,32 Md | |
| -12,29 % | 10,68 Md |
Biotechnological and medical research – Others
